Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ

The objective of this clinical trial is to evaluate the safety and tolerability of BY002 in healthy subjects. Investigators will compare BY002 to a placebo (a pharmacologically inactive substance) to assess the safety and tolerability of BY002 in healthy subjects. Participants will undergo: 1. Single/multiple subcutaneous (SC) administrations of BY002/placebo 2. A 7-day safety follow-up period following the last dose

NCT Number	NCT07640438
Lead Sponsor	First Affiliated Hospital of Zhejiang University Collaborators: SDM Bioservices Inc., Beijing Hikinge Pharmaceutical Technology Co., Ltd., Biyopharma Co., LTD，Hangzhou， China
Conditions	Healthy Participants Study
Enrollment	104 participants
Start Date	2026-06-01
Primary Completion	2026-11-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-10